Brief: Shanghai Henlius Biotech Enters License Agreement With Sandoz For Hlx13

Sandoz AG

29/04/2025 11:11

April 29 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:

ENTERS LICENSE AGREEMENT WITH SANDOZ FOR HLX13

SANDOZ GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE HLX13 IN MULTIPLE REGIONS

SANDOZ TO PAY HENLIUS $31 MILLION UPFRONT

TO RECEIVE UP TO $270 MILLION IN MILESTONE PAYMENTS

Further company coverage: 2696.HK

 ((Reuters.Briefs@thomsonreuters.com;))